136 results
8-K
EX-10.2
5kp9alftwwcg 45
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
59lll telyg
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
jhzd0k5x0ulvayr8f2z
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
kxgwtl
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
oqm9xasxedqtelnb1
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
mz4k0c 7j1
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
916jrch 546xv
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
vcmbb8tnekj dc
30 May 23
Business combination disclosure
4:21pm
8-K
o4vio6s5xt2gborw0f
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
dm4oldmoti12l209
22 May 23
Business combination disclosure
7:01am
8-K
a0ldfkvrfl7t
22 May 23
Other Events
6:59am
8-K
EX-99.1
gu3eqtto9w6q8bczfmr
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
74xde 984gloqk
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
bshjbfz27bw4anbc4a0
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm